Category Archives: Strategy

Cost Cutting No Longer Main Driver of Outsourcing

Biopharmaceutical companies have traditionally considered outsourcing as a way to control costs and manage their internal resources to make the core activities left in-house more efficient. But in recent years, surveys of biopharmaceutical manufacturers by BioPlan Associates have shown that cost cutting is, by far, not the primary reason companies outsource anymore. In fact, this […]
Posted in Strategy | Tagged , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, pricing, Regulatory | Tagged , , | 1 Comment

The Long Tail: Behind This Year's Pharm Exec 50

Therapeutic specialization, competitive differentiation, and a finely-tailored value proposition are creating a new drug world of bespoke market niches—and infinite future possibilities for the best of this year’s Pharma 50. The vigorous return of M&A activity to biopharmaceuticals this year brings us back to the question that industry strategists have been posing for years: is […]
Also posted in Op-Ed | Tagged , , , , | Leave a comment

Pharma Should be at Heart of European Economic Reform, says EFPIA

The European Federation of Pharmaceutical Industries and Associations (EFPIA) yesterday launched what it called “a landmark paper” outlining steps towards an integrated strategy for the life sciences sector in Europe. “Health & Growth — Working together for a healthy Europe” calls for a new generation of partnerships to address the EU’s growing health and competitiveness challenges. The […]
Also posted in Europe, Global | Tagged , , , , | Leave a comment

Investment in Pharma Sales “Flat” in 2013

Industry investment in pharma sales force and marketing channels remained “flat” in 2013 at just under €85 billion constant US dollars, according to newly released data from Cegedim Strategic Data (CSD).
Also posted in Emerging Markets, Europe, Global, Marketing, Sales | Tagged , , , | Leave a comment
  • Categories

  • Meta